Eris Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has received a show cause cum demand notice from the Directorate General of GST Intelligence (DGGI), Mumbai, alleging non-payment of Integrated GST (IGST) under the reverse charge mechanism on import of services. The notice relates to the company's 2019 acquisition of trademark rights for the diabetes brand 'Zomelis' and associated brands from Novartis AG, Switzerland. The tax demand amounts to Rs. 16.85 crore, with interest charged at 18% per annum from November 27, 2019. No penalty has been specified in the notice yet. The company is evaluating the matter with its tax consultants and plans to submit a reply within the prescribed period, stating it believes it has a strong case on merits.
This is an early-stage tax dispute and not an adverse order. If the demand is upheld, it could mean an outgo of around Rs. 16.85 crore plus nearly six years of interest, which may impact short-term earnings. However, since the company intends to contest it and views its position as strong, investors should monitor the outcome but no immediate financial hit is required.